LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced that the U.S. Food and Drug Administration (FDA) has accepted
for review the New Drug Application (NDA) for its lead product candidate
PB272 (neratinib) for the extended adjuvant treatment of patients with
early stage HER2-overexpressed/amplified breast cancer who have received
prior adjuvant trastuzumab (Herceptin®)-based therapy.
“The FDA acceptance of ourmore...